3-methoxy-4-hydroxyphenylalanine (3-O-methyldopa) in plasma during oral L-dopa therapy of patients with Parkinson's disease.
D000284:Administration, Oral; D000535:Aluminum; D002021:Buffers; D002845:Chromatography; D002852:Chromatography, Ion Exchange; D004295:Dihydroxyphenylalanine / Q000008:administration & dosage / Q000097:blood / Q000627:therapeutic use*; D005215:Fasting; D006801:Humans; D006863:Hydrogen-Ion Concentration; D007700:Kinetics; D008722:Methods; D008750:Methyldopa / Q000097:blood*; D010300:Parkinson Disease / Q000097:blood* / Q000188:drug therapy; D010648:Phenylacetates / Q000097:blood; D013050:Spectrometry, Fluorescence
D002021:Buffers; D010648:Phenylacetates; D008750:Methyldopa; D004295:Dihydroxyphenylalanine; D000535:Aluminum